- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05687890
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
A Randomized, Double Blind, Placebo Parallel Controlled, 2 Cohorts, Multicenter Phase II Study to Investigate the Safety and Efficacy of SC0062 Capsule in Patients With Chronic Kidney Disease With Albuminuria
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This multicenter, randomized, double blind, placebo parallel controlled, 2 cohorts phase II study will contain 2 cohorts:
Cohort 1: diabetic kidney disease Cohort 2: biopsy-proven IgAN In each cohort, approximately 120 patients will be randomized to receive SC0062 or placebo daily for 24 weeks.
The objective of this study is to evaluate the preliminary efficacy and safety of SC0062 capsules compared to placebo in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy) with albuminuria who are treated with the maximum tolerated labeled dose renin-angiotensin system inhibitor (RASi).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jianghua Chen, Prof
- Phone Number: 13905814085
- Email: chenjianghua@zju.edu.cn
Study Contact Backup
- Name: Xiaoying Du, Doc.
- Phone Number: 13588413101
- Email: Zyyyrct2010@163.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- 79 Qingchun Rd.,Shangcheng District
-
Contact:
- Jianghua Chen, Prof.
- Phone Number: 13905814085
- Email: chenjianghua@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Sign the informed consent voluntarily, and fully understand and comply with the relevant procedures of the test;
2. Age range from 18 to 70 years old (including the critical value), gender is not limited;
3. Patients with chronic kidney disease (CKD) stage G2~G3a with albuminuria, requirements:
- eGFR ≥ 45 mL/min/1.73m^2 and < 90mL/min/1.73m^2 at Screening based on the CKD-EPI equation..
- Receiving a maximally tolerated dose of RAS inhibitor therapy (ACEi or ARB) that has been stable for at least 12 weeks; If an SGLT2i is prescribed, the dose must be stable or only slight changes from 4 weeks prior before randomization to the end of treatment (per Investigator judgement) .
- Cohort 1: Diagnosed with type 2 diabetes mellitus and receiving at least one hypoglycemic agent in the 12 months prior to randomization; In accordance with the diagnostic criteria of DKD, urine albumin to creatinine ratio (UACR) ≥300 mg/g and < 1500 mg/g during at screening.
- Cohort 2: Biopsy-proven IgA nephropathy; Urine protein-creatinine ratio (UPCR) ≥0.5g/g and < 2.5 g/g at screening.
4. Laboratory parameters meet the following criteria:
- Serum albumin ≥30 g/L;
- Hemoglobin value ≥90 g/L; Platelet ≥80×10^9/L;
- Brain natriuretic peptide (BNP) ≤ 200 pg/mL;
- Blood potassium ≤ 5.5 mmol/L;
- Systolic blood pressure (SBP) ≤140 mmHg; Diastolic blood pressure (DBP) ≤90 mmHg;
- Hemoglobin A1c (HbA1c) ≤ 10% (cohort 1)/Hemoglobin A1c (HbA1c) < 6.5% (cohort 2);
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2×ULN; Total bilirubin ≤1.5ULN;
5. All participants should follow protocol defined contraceptives procedures.
Exclusion Criteria:
- Women who were pregnant or breastfeeding; A WOCBP who has a positive blood pregnancy test (within 72 hours) prior to randomization;
- Patients who are allergic to or are allergic to any component of the study drug (SC0062 capsules);
- Systemic use of corticosteroids or immunosuppressants within 3 months prior to randomization;
- Other causes of chronic kidney disease are also diagnosed; 5.1 Type diabetes or other specific types of diabetes;
6. Secondary IgA nephropathy;
7. Clinical suspicion of rapidly progressive glomerulonephritis (RPGN);
8. Diagnosed with nephrotic syndrome;
9. Have a history of pulmonary hypertension, pulmonary fibrosis or any lung disease requiring oxygen therapy (e.g., chronic obstructive pulmonary disease, emphysema, pulmonary edema, etc.);
10. Subjects who had received endothelin receptor antagonist in the past;
11. History of moderate or severe edema, non-traumatic facial edema, or myxoid edema within the 6 months prior to randomization;
12. History of orthostatic hypotension within 6 months prior to randomization;
13. History of clinically significant cirrhosis;
14. History of heart failure or previous hospital admissions due to fluid overload;
15. History of renal transplantation or other organ transplantation;
16. Hypothyroidism (except subclinical hypothyroidism or stable hypothyroidism after hormone replacement therapy);
17. Patients who have the potential to interfere with oral drug absorption, such as subtotal gastrectomy, clinically severe gastrointestinal disease, or certain types of bariatric surgery, such as gastric bypass surgery, that do not involve simply separating the stomach into a separate chamber, such as gastric banding surgery;
18. Use of potent CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's Burt) and potent CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, voriconazole, clarithromycin, telomycin, nefazodone, ritonavir, saquinavir) within 1 month before randomization;
19. Active hepatitis B; active hepatitis C; active syphilis; positive HIV serum reaction.
20. Malignancy within the past 5 years.;
21.Alcohol or drug abuse or dependence, or a history of psychological disorder;
22. Participants participated in clinical trials of other investigational drugs or medical devices within 3 months prior to randomization;
23. Any other clinically significant clinical condition, or medical history may interfere with the subject's safety, study evaluation, and/or study procedures per the judgment by the investigator;
24. The investigator believes that the subject has any other reasons for not being eligible to participate in this clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SC0062 low dose group
Subjects will take two capsules daily for 24 weeks during the treatment period
|
Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
|
Experimental: SC0062 medium dose group
Subjects will take two capsules daily for 24 weeks during the treatment period
|
Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
|
Experimental: SC0062 high dose group
Subjects will take two capsules daily for 24 weeks during the treatment period
|
Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
|
Placebo Comparator: Placebo of SC0062 group
Subjects will take two capsules daily for 24 weeks during the treatment period
|
Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in urine albumin creatinine ratio (UACR) at Week 12
Time Frame: Week 12
|
Change from baseline to Week12 in urine albumin creatinine ratio (UACR)
|
Week 12
|
Changes in urine protein creatinine ratio (UPCR) at Week 12
Time Frame: Week 12
|
Change from baseline to Week12 in urine protein creatinine ratio (UPCR)
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in urine albumin creatinine ratio (UACR) by visit
Time Frame: Week 2, week 4, week 8, week 12, week 16, week 20, week 24
|
Change in urine albumin creatinine ratio (UACR) after treatment
|
Week 2, week 4, week 8, week 12, week 16, week 20, week 24
|
Change in urine protein creatinine ratio (UPCR) by visit
Time Frame: Week 2, week 4, week 8, week 12, week 16, week 20, week 24
|
Change in urine protein creatinine ratio (UPCR) after treatment
|
Week 2, week 4, week 8, week 12, week 16, week 20, week 24
|
Changes in glomerular filtration rate (eGFR)
Time Frame: Week 2, week 4, week 8, week 12, week 16, week 20, week 24
|
Change in glomerular filtration rate (eGFR) from baseline to end of study
|
Week 2, week 4, week 8, week 12, week 16, week 20, week 24
|
Change of 24-hour urine albumin excretion rate (UAER)
Time Frame: Week 12, week 24
|
Change of 24-hour urine albumin excretion rate (UAER) at Week 12 and Week 24
|
Week 12, week 24
|
Percentage of subjects achieving UACR ≥30%, ≥40%, and ≥50% reduction from baseline
Time Frame: Week 12, week 24
|
Percentage of subjects achieving UACR ≥30%, ≥40%, and ≥50% reduction at Week 12 and Week 24
|
Week 12, week 24
|
Percentage of subjects achieving UPCR ≥30%, ≥40%, and ≥50% reduction from baseline
Time Frame: Week 12, week 24
|
Percentage of subjects achieving UPCR ≥30%, ≥40%, and ≥50% reduction at Week 12 and Week 24
|
Week 12, week 24
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jianghua Chen, Prof, Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Urologic Diseases
- Endocrine System Diseases
- Disease Attributes
- Diabetes Complications
- Diabetes Mellitus
- Renal Insufficiency
- Nephritis
- Glomerulonephritis
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Renal Insufficiency, Chronic
- Diabetic Nephropathies
- Glomerulonephritis, IGA
Other Study ID Numbers
- SC0062-202
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Kidney Disease
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
Omar Tarek ElfarargiNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...Not yet recruitingEstablishment and Clinical Validation of a New Technique for Early Diagnosis of Diabetic NephropathyDiabetes Mellitus | Diabetic Kidney Disease | Biomarkers | Early Diagnosis
-
Fayoum UniversityCairo UniversityNot yet recruitingSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Mayo ClinicRegenerative Medicine MinnesotaTerminatedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Kidney Disease | Diabetic Nephropathies | Chronic Kidney Disease | Kidney Failure | Diabetic Nephropathy Type 2 | Kidney InsufficiencyUnited States
-
CSL BehringCompletedDiabetic Kidney Disease (DKD)United States, Australia, New Zealand, Puerto Rico, Canada, Israel
-
Universidad Estatal de MilagroSecretaría de Ciencia, Tecnología e Innovación (Senescyt); PROMETEOUnknownKidney Diseases | Diabetes Mellitus | Diabetic Nephropathy | Diabetic Kidney Disease | Chronic Kidney DiseaseEcuador
-
University of California, San DiegoRecruiting
Clinical Trials on SC0062 low dose
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
Indonesia UniversityMedika Natura Sdn BhdCompleted
-
Postgraduate Institute of Medical Education and...Completed
-
Yiling Pharmaceutical Inc.CompletedPharmacokinetics | Healthy Adult Subjects | Safety and TolerabilityUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingLung CarcinomaUnited States
-
CalciMedica, Inc.CompletedSystemic Inflammatory Response Syndrome | Acute PancreatitisUnited States